Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic TCRa/b-depleted HA-1 minor histocompatibility antigen-reactive TCR-modified RQR8-expressing T cells BSB-1001

A preparation of T-cell receptor (TCR) alpha and beta (TCRa/b)-depleted donor-derived T lymphocytes that have been transduced with a lentivirus vector encoding a TCR specific for HLA-A*02:01-restricted minor histocompatibility antigen HA-1 (HA1) and expressing RQR8, with potential immunomodulating and antineoplastic activities. Following HLA-matched allogeneic hematopoietic cell transplantation (HCT) in HLA-A*02:01 positive patients, allogeneic TCRa/b-depleted HA-1 minor histocompatibility antigen-reactive TCR-modified RQR8-expressing T cells BSB-1001 specifically recognize and bind to HA-1 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing HLA-A*02:01 HA-1. HA-1 is a lineage-specific antigen found on leukemia cells. BSB-1001 carries the universal RQR8 safety "off" switch, which allows selective removal of the T-cells through both complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) following administration of rituximab if unacceptable side-effects occur. CRISPR-cas9 editing of the donor T cells deletes the endogenous TCRa/b chains. Depletion of TCRa/b increases expression of the transduced TCR and reduces risk of graft-versus-host disease (GVHD) caused by native TCRs.
Synonym:allogeneic anti-HA-1 T cells BSB-1001
allogeneic anti-HA-1 TCR-engineered T cells BSB-1001
allogeneic anti-miHA-1 TCR lentivector transduced T cells BSB-1001
allogeneic HA-1-targeting TCR T cells BSB-1001
allogeneic miHA-reactive TCR-modified T cells BSB-1001
T-cell receptor engineered donor T cells BSB-1001
Code name:BSB 1001
BSB-1001
BSB1001
Search NCI's Drug Dictionary